|
1
|
Haggar FA and Boushey RP: Colorectal
cancer epidemiology: Incidence, mortality, survival, and risk
factors. Clin Colon Rectal Surg. 22:191–197. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Connell O JB, Maggard MA and Ko CY: Colon
cancer survival rates with the new American Joint Committee on
Cancer sixth edition staging. J Natl Cancer Inst. 96:1420–1425.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Kraus S, Nabiochtchikov I, Shapira S and
Arber N: Recent advances in personalized colorectal cancer
research. Cancer Lett. 347:15–21. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Ferlay J, Shin HR, Bray F, Forman D,
Mathers C and Parkin DM: Estimates of worldwide burden of cancer in
2008: GLOBOCAN, 2008. Int J Cancer. 127:2893–2917. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Mármol I, Sánchez-de-Diego C, Dieste
Pradilla A, Cerrada E and Yoldi Rodriguez MJ: Colorectal carcinoma:
A general overview and future perspectives in colorectal cancer.
Int J Mol Sci. 18:pii: E197. 2017. View Article : Google Scholar
|
|
6
|
Venook A: Critical evaluation of current
treatments in metastatic colorectal cancer. Oncologist. 10:250–261.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Van Cutsem E, Cervantes A, Nordlinger B
and Arnold D: ESMO guidelines working group: Metastatic colorectal
cancer: ESMO clinical practice guidelines for diagnosis, treatment
and follow-up. Ann Oncol. 3 25 Suppl:iii1–iii9. 2014. View Article : Google Scholar
|
|
8
|
Lee JJ, Beumer JH and Chu E: Therapeutic
drug monitoring of 5-fluorouracil. Cancer Chemother Pharmacol.
78:447–464. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Liu M and Chen H: The role of microRNAs in
colorectal cancer. J Genet Genomics. 37:347–358. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Kempin S: Update on chronic lymphocytic
leukemia: Overview of new agents and comparative analysis. Curr
Treat Options Oncol. 14:144–155. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Di Leva G, Cheung DG and Croce CM: miRNA
clusters as therapeutic targets for hormone-resistant breast
cancer. Expert Rev Endocrinol Metab. 10:607–617. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Grady WM and Carethers JM: Genomic and
epigenetic instability in colorectal cancer pathogenesis.
Gastroenterology. 135:1079–1099. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Karakatsanis A, Papaconstantinou I,
Gazouli M, Lyberopoulou A, Polymeneas G and Voros D: Expression of
microRNAs, miR-21, miR-31, miR-122, miR-145, miR-146a, miR-200c,
miR-221, miR-222, and miR-223 in patients with hepatocellular
carcinoma or intrahepatic cholangiocarcinoma and its prognostic
significance. Mol Carcinog. 52:297–303. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Li Y, Li W, Ouyang Q, Hu S and Tang J:
Detection of lung cancer with blood microRNA-21 expression levels
in Chinese population. Oncol Lett. 2:991–994. 2011.PubMed/NCBI
|
|
15
|
Zhang BG, Li JF, Yu BQ, Zhu ZG, Liu BY and
Yan M: microRNA-21 promotes tumor proliferation and invasion in
gastric cancer by targeting PTEN. Oncol Rep. 27:1019–1026. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Papagiannakopoulos T, Shapiro A and Kosik
KS: MicroRNA-21 targets a network of key tumor-suppressive pathways
in glioblastoma cells. Cancer Res. 68:8164–8172. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Liu GH, Zhou ZG, Chen R, Wang MJ, Zhou B,
Li Y and Sun XF: Serum miR-21 and miR-92a as biomarkers in the
diagnosis and prognosis of colorectal cancer. Tumour Biol.
34:2175–2181. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Asangani IA, Rasheed SA, Nikolova DA,
Leupold JH, Colburn NH, Post S and Allgayer H: MicroRNA-21 (miR-21)
post-transcriptionally downregulates tumor suppressor Pdcd4 and
stimulates invasion, intravasation and metastasis in colorectal
cancer. Oncogene. 27:2128–2136. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Zhang HL, Yang LF, Zhu Y, Yao XD, Zhang
SL, Dai B, Zhu YP, Shen YJ, Shi GH and Ye DW: Serum miRNA-21:
Elevated levels in patients with metastatic hormone-refractory
prostate cancer and potential predictive factor for the efficacy of
docetaxel-based chemotherapy. Prostate. 71:326–331. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Dillhoff M, Liu J, Frankel W, Croce C and
Bloomston M: MicroRNA-21 is overexpressed in pancreatic cancer and
a potential predictor of survival. J Gastrointest Surg.
12:2171–2176. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Faragalla H, Youssef YM, Scorilas A,
Khalil B, White NM, Mejia-Guerrero S, Khella H, Jewett MA, Evans A,
Lichner Z, et al: The clinical utility of miR-21 as a diagnostic
and prognostic marker for renal cell carcinoma. J Mol Diagn.
14:385–392. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Kumar S, Keerthana R, Pazhanimuthu A and
Perumal P: Overexpression of circulating miRNA-21 and miRNA-146a in
plasma samples of breast cancer patients. Indian J Biochem Biophys.
50:210–214. 2013.PubMed/NCBI
|
|
23
|
Zhu Q, Wang Z, Hu Y, Li J, Li X, Zhou L
and Huang Y: miR-21 promotes migration and invasion by the
miR-21-PDCD4-AP-1 feedback loop in human hepatocellular carcinoma.
Oncol Rep. 27:1660–1668. 2012.PubMed/NCBI
|
|
24
|
Liu CZ, Liu W, Zheng Y, Su JM, Li JJ, Yu
L, He XD and Chen SS: PTEN and PDCD4 are bona fide targets of
microRNA-21 in human cholangiocarcinoma. Chin Med Sci J. 27:65–72.
2012.PubMed/NCBI
|
|
25
|
Wang N, Zhang CQ, He JH, Duan XF, Wang YY,
Ji X, Zang WQ, Li M, Ma YY, Wang T and Zhao GQ: MiR-21
down-regulation suppresses cell growth, invasion and induces cell
apoptosis by targeting FASL, TIMP3, and RECK genes in esophageal
carcinoma. Dig Dis Sci. 58:1863–1870. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Feng YH, Wu CL, Shiau AL, Lee JC, Chang
JG, Lu PJ, Tung CL, Feng LY, Huang WT and Tsao CJ:
MicroRNA-21-mediated regulation of Sprouty2 protein expression
enhances the cytotoxic effect of 5-fluorouracil and metformin in
colon cancer cells. Int J Mol Med. 29:920–926. 2012.PubMed/NCBI
|
|
27
|
Zhang HZ, Kasibhatla S, Wang Y, Herich J,
Guastella J, Tseng B, Drewe J and Cai SX: Discovery,
characterization and SAR of gambogic acid as a potent apoptosis
inducer by a HTS assay. Bioorg Med Chem. 12:309–317. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Wang X and Chen W: Gambogic acid is a
novel anti-cancer agent that inhibits cell proliferation,
angiogenesis and metastasis. Anticancer Agents Med Chem.
12:994–1000. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Ishaq M, Khan MA, Sharma K, Sharma G,
Dutta RK and Majumdar S: Gambogic acid induced oxidative stress
dependent caspase activation regulates both apoptosis and autophagy
by targeting various key molecules (NF-κB, Beclin-1, p62 and NBR1)
in human bladder cancer cells. Biochim Biophys Acta.
1840:3374–3384. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Lü L, Tang D, Wang L, Huang LQ, Jiang GS,
Xiao XY and Zeng FQ: Gambogic acid inhibits TNF-α-induced invasion
of human prostate cancer PC3 cells in vitro through PI3K/Akt and
NF-κB signaling pathways. Acta Pharmacol Sin. 33:531–541. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Wang LH, Li Y, Yang SN, Wang FY, Hou Y,
Cui W, Chen K, Cao Q, Wang S, Zhang TY, et al: Gambogic acid
synergistically potentiates cisplatin-induced apoptosis in
non-small-cell lung cancer through suppressing NF-κB and MAPK/HO-1
signalling. Br J Cancer. 110:341–352. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Zhang H, Lei Y, Yuan P, Li L, Luo C, Gao
R, Tian J, Feng Z, Nice EC and Sun J: ROS-mediated autophagy
induced by dysregulation of lipid metabolism plays a protective
role in colorectal cancer cells treated with gambogic acid. PLoS
One. 9:e964182014. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Huang GM, Sun Y, Ge X, Wan X and Li CB:
Gambogic acid induces apoptosis and inhibits colorectal tumor
growth via mitochondrial pathways. World J Gastroenterol.
21:6194–6205. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Hu Y, Yang Y, You QD, Liu W, Gu HY, Zhao
L, Zhang K, Wang W, Wang XT and Guo QL: Oroxylin A induced
apoptosis of human hepatocellular carcinoma cell line HepG2 was
involved in its antitumor activity. Biochem Biophys Res Commun.
351:521–527. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Ni W, Fang Y, Tong L, Tong Z, Yi F, Qiu J,
Wang R and Tong X: Girdin regulates the migration and invasion of
glioma cells via the PI3K-Akt signaling pathway. Mol Med Rep.
12:5086–5092. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Justus CR, Leffler N, Ruiz-Echevarria M
and Yang LV: In vitro cell migration and invasion assay. J Vis Exp.
88:2014.
|
|
37
|
Li W, Qiu T, Zhi W, Shi S, Zou S, Ling Y,
Shan L, Ying J and Lu N: Colorectal carcinomas with KRAS codon 12
mutation are associated with more advanced tumor stages. BMC
Cancer. 15:3402015. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Ogino S, Nosho K, Kirkner GJ, Kawasaki T,
Meyerhardt JA, Loda M, Giovannucci EL and Fuchs CS: CpG island
methylator phenotype, microsatellite instability, BRAF mutation and
clinical outcome in colon cancer. Gut. 58:90–96. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Munro AJ, Lain S and Lane DP: P53
abnormalities and outcomes in colorectal cancer: A systematic
review. Br J Cancer. 92:434–444. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Ahmed FE, Ahmed NC, Vos PW, Bonnerup C,
Atkins JN, Casey M, Nuovo GJ, Naziri W, Wiley JE, Mota H and
Allison RR: Diagnostic microRNA markers to screen for sporadic
human colon cancer in stool: I. Proof of principle. Cancer Genomics
Proteomics. 10:93–113. 2013.PubMed/NCBI
|
|
41
|
Kashyap D, Mondal R, Tuli HS, Kumar G and
Sharma AK: Molecular targets of gambogic acid in cancer: Recent
trends and advancements. Tumor Biol. 37:12915–12925. 2016.
View Article : Google Scholar
|
|
42
|
Yang Y, Sun X, Yang Y, Yang X, Zhu H, Dai
S, Chen X, Zhang H, Guo Q, Song Y, et al: Gambogic acid enhances
the radiosensitivity of human esophageal cancer cells by inducing
reactive oxygen species via targeting Akt/mTOR pathway. Tumor Biol.
37:1853–1862. 2016. View Article : Google Scholar
|
|
43
|
Yu J, Guo QL, You QD, Zhao L, Gu HY, Yang
Y, Zhang HW, Tan Z and Wang X: Gambogic acid-induced G2/M phase
cell-cycle arrest via disturbing CDK7-mediated phosphorylation of
CDC2/p34 in human gastric carcinoma BGC-823 cells. Carcinogenesis.
28:632–638. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Yu J, Guo QL, You QD, Lin SS, Li Z, Gu HY,
Zhang HW, Tan Z and Wang X: Repression of telomerase reverse
transcriptase mRNA and hTERT promoter by gambogic acid in human
gastric carcinoma cells. Cancer Chemother Pharmacol. 58:434–443.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Felth J, Lesiak-Mieczkowska K, D'Arcy P,
Haglund C, Gullbo J, Larsson R, Linder S, Bohlin L, Fryknäs M and
Rickardson L: Gambogic acid is cytotoxic to cancer cells through
inhibition of the ubiquitin-proteasome system. Invest New Drugs.
31:587–598. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Meng F, Henson R, Wehbe-Janek H, Ghoshal
K, Jacob ST and Patel T: MicroRNA-21 regulates expression of the
PTEN tumor suppressor gene in human hepatocellular cancer.
Gastroenterology. 133:647–658. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Cao L, Chen J, Ou B, Liu C, Zou Y and Chen
Q: GAS5 knockdown reduces the chemo-sensitivity of non-small cell
lung cancer (NSCLC) cell to cisplatin (DDP) through regulating
miR-21/PTEN axis. Biomed Pharmacother. 93:570–579. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Salmena L: PTEN: History of a tumor
suppressor. Methods Mol Biol. 1388:3–11. 2016. View Article : Google Scholar : PubMed/NCBI
|
